$BTMD

biote Corp.

0
1
0
$202K
Beer Marc D
0%
See all $BTMD insider activity →
Low

biote Corp. (BTMD) gains new investor with 5.9% stake

Amit Agarwal, a U.S. private investor, disclosed a 5.92% stake in biote Corp. (BTMD), owning 1.7 million Class A shares with sole voting and dispositive power. The filing was made via a Schedule 13G on August 28, 2026.

Beer Marc D purchased $202K of BTMD

Beer Marc D (Executive Chairman) purchased 131,950 shares of biote Corp. (BTMD) at an average of $1.53 ($1.53–$1.55, $0.20M total) across 2 trades over 2026-08-10 to 2026-08-11.

biote Q2 Earnings Call Highlights

Biote (NASDAQ: BTMD) reported Q2 net loss of $7.4M ($0.23/share) versus prior-year net income of $3.9M, and adjusted EBITDA of $5.6M (12.6% margin). Gross margin fell to 65.4% from 71.6% due to higher-cost third-party pellets during a disruption and $600k recall-related costs. Biote cut its 2026 outlook to revenue above $175M and adjusted EBITDA above $25M.

BTMD sentiment & insider activity

Over the past 7 days, alphai's AI scored 1 news story mentioning BTMD (biote Corp.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent BTMD coverage spans financial news, earnings and insider activity.

In the last 30 days, BTMD insiders filed 2 SEC Form 4 transactions — 2 purchases ($202K) and no sales. The most active reporter was Beer Marc D, Executive Chairman, with 2 filings.

What's driving BTMD

  • New sizable shareholder could influence future corporate actions or board composition.

    stocktitan.net · Aug 28, 2026

  • Insider open-market buying is a modest bullish signal, but it is not a fundamental catalyst like earnings or guidance.

    SEC EDGAR · Aug 12, 2026

  • Q2 results and guidance reset the near-term profitability outlook, with margin pressure tied to third-party pellet sourcing and legal costs.

    yahoo.com · Aug 7, 2026

  • The recall-driven revenue and margin pressure plus guidance revision create a near-term earnings risk and a second-half recovery narrative.

    SEC EDGAR 8-K · Aug 5, 2026

  • Biote Corp. reported a decline in revenue by 8.3% year-over-year, missing analyst estimates, but achieved a higher-than-expected EPS of $0.06. The company also reduced liquidity and capital expenditure, indicating potential financial strain.

    Quiver Quantitative · May 6, 2026

alphai scores every news story that mentions BTMD with an AI model for sentiment and relevance, and aggregates insider trades from biote Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BTMD

Score
$BTMDMed

biote Q2 Earnings Call Highlights

Biote (NASDAQ: BTMD) reported Q2 net loss of $7.4M ($0.23/share) versus prior-year net income of $3.9M, and adjusted EBITDA of $5.6M (12.6% margin). Gross margin fell to 65.4% from 71.6% due to higher-cost third-party pellets during a disruption and $600k recall-related costs. Biote cut its 2026 outlook to revenue above $175M and adjusted EBITDA above $25M.

biote Corp. (BTMD): Results of Operations and Financial Condition

biote Corp. (BTMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Biote Reports Second Quarter 2026 Financial Results Continued progress in advancing strategic initiatives Updates full-year outlook Second Quarter 2026 Financial Highlights • Revenue of $44.2 million • Gross profit margin of 65.4% • Net loss of $(7.4) million and diluted loss per

$BTMDLow

Biote (BTMD) details 2026 virtual meeting, board elections and pay

Biote Corp. (BTMD) has announced its 2026 annual virtual stockholder meeting for May 12, 2026, where shareholders will vote on electing two Class I directors and ratifying Deloitte & Touche LLP as its independent auditor. The proxy statement also provided details on board composition, corporate governance, and executive and director compensation, including stock option awards and bonuses tied to the company's 2025 performance. Key financial figures and beneficial ownership information were also disclosed.

biote (BTMD) Balance Sheet & Financial Health Metrics

This article provides an overview of biote (BTMD)'s financial health and balance sheet metrics. It highlights key figures such as a negative shareholder equity of $-50.4M and total debt of $107.0M, resulting in a debt-to-equity ratio of -212.4%. The company's EBIT is $35.1M, with an interest coverage ratio of 3.2, and it holds $24.1M in cash and short-term investments.

Related tickers